I-125 monoclonal antibody A33

Drug Profile

I-125 monoclonal antibody A33

Alternative Names: A33-radionuclides; CDP 833; hA33 90Y

Latest Information Update: 25 Jan 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celltech Group
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Colorectal cancer

Most Recent Events

  • 25 Jan 1999 Discontinued-I for Colorectal cancer in USA (IV)
  • 01 Oct 1997 A study has been added to the therapeutic trials and adverse events sections
  • 20 Aug 1997 CDP 833 is now called I-125 monoclonal antibody A33
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top